Heron Therapeutics (HRTX) PT Lowered to $13 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
March 1, 2022 7:22 AM ESTCantor Fitzgerald analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreHeron Therapeutics (HRTX) PT Lowered to $16 at Needham & Company on Financial Overhang Concerns
March 1, 2022 6:31 AM ESTNeedham & Company analyst Serge Belanger lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $16.00 (from $24.00) while maintaining a Buy rating, following the company's most recent quarterly report.
The analyst quotes: "HRTX's 4Q21 disappointed with Zynrelef sales of $0.8MM (vs. $2.1MM in... More
Bitnile (NILE) Issues February 2022 Mining Update
March 1, 2022 6:31 AM ESTBitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (BitNile or the Company) today published an unaudited update on Bitcoin production and miner installation. The number of miners and production capacity metrics within this press release represent the S19j Pro Antminers at the Michigan data center. BitNiles Bitcoin mining production is currently operating at an... More
Heron Therapeutics (HRTX) PT Lowered to $40 at Evercore ISI
March 1, 2022 4:32 AM ESTEvercore ISI lowered its price target on Heron Therapeutics (NASDAQ: HRTX) to $40.00 (from $60.00) while maintaining a Outperform rating.... More
Heron Therapeutics (HRTX) Tops Q4 EPS by 4c
February 28, 2022 4:28 PM ESTHeron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.
For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.
... More